IL-33 binding to the receptor suppression of tumorigenicity 2 (ST2) produces proinflammatory and anti-inflammatory effects. Increased levels of soluble ST2 (sST2) are a biomarker for steroid-refractory GVHD and mortality. However, whether sST2 has a role as an immune modulator or only as a biomarker during GVHD was unclear. We show increased IL-33 production by non-hematopoietic cells in the GI tract in mice postconditioning and patients during GVHD. Exogenous IL-33 administration during the peak inflammatory response worsened GVHD. Conversely, GVHD lethality and TNF-α production was significantly reduced in il33 -/-recipients. ST2 was upregulated on murine and human alloreactive T cells and sST2 increased as experimental GVHD progressed. 
Introduction
For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From IL-33, a member of the IL-1 superfamily, is a multifunctional protein with immune modulating roles as an alarmin and pleiotropic cytokine.
IL-33 is expressed predominantly in fibroblasts, endothelial cells, and epithelial cells; however upon inflammatory stimuli its production is increased and expression has been seen in myeloid cells. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Unlike other members of the IL-1 superfamily, IL-33 is cleaved by caspase-3 and caspase-7 into a biologically inactive form during apoptosis, but is functional when released in its full-length form by necrosis. [11] [12] [13] [14] [15] IL-33 binds to its receptor ST2, which has three known isoforms; a membrane bound, soluble, and variant form. [16] [17] [18] [19] 55, 56 The soluble form of the receptor, sST2, acts
For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From as a decoy receptor blocking IL-33 signaling 33, 57 and inhibiting LPS induced cytokine production. [4] [5] [6] [7] [8] [9] [10] 58, 59 Previous observations in other models of inflammation have shown IL-33 to be either pro-inflammatory or anti-inflammatory depending on the disease entity. A proinflammatory role for IL-33 was found in respiratory syncytial virus infection, 1,3,45 and neutralizing antibodies against ST2 attenuated lung inflammation. 11, 45 A proinflammatory role for IL-33 was also reported in the pathogenesis of rheumatoid arthritis, 16 ,60 mast cell-induced airway inflammation, 20, 61 allergic sensitization 30, 62 and inflammatory bowel disease. 34, 35, 63 Conversely, IL-33 was shown to protect against atherosclerosis through the induction of IL-5, 2,6,13-15 was cardioprotective, 4, 12, 18, 19 promoted cardiac allograft survival 3, 17, [22] [23] [24] [25] [26] [27] [28] [29] 31 and had either no effect on experimental autoimmune encephalomyelitis 17, 45 or even reduced its severity. 47, 64 Elevated levels of the soluble form of the IL-33 receptor, sST2, have been shown in several pathologies, including asthma, 49, 51, 59 cardiovascular disease, [52] [53] [54] 65 and autoimmune disorders. 50, 55 Recent evidence suggests a new role for IL-33 in graft-versus-host disease (GVHD), wherein the donor T cells cause destruction of recipient tissues after allogeneic hematopoietic cell transplantation (HCT). Acute GVHD is characterized by damage to the skin, liver, and gastrointestinal (GI) tract. These mucosal barrier tissues store large amounts of IL-33 that may be released upon tissue injury. 33, [66] [67] [68] [69] [70] Recently, elevated levels of sST2 as early as day 14 post conditioning prior to the development of GVHD has been identified as a biomarker for increased mortality and steroid-refractory GVHD. [4] [5] [6] [7] [8] [9] [10] 59 Yet little is known of the role of IL-33 in the immune responses shaping GVHD. Here we explore the potential role of IL-33, ST2L and sST2 in acute GVHD pathogenesis.
Methods
Human subjects. We collected all of the samples after approval by the Ethics committee of the Albert-Ludwigs-University Freiburg, Germany (Protocol number: 480/11) and after
For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From obtaining written informed consent in accordance with the Declaration of Helsinki.
Intestinal tissue biopsies were collected in a prospective manner from individuals undergoing allo-HCT with or without GVHD. The grading of human GVHD was performed on the basis of histopathology.
Mice. WT mice were purchased from several different vendors depending on the university conducting the experiment. BALB/c and C57BL/6 mice were purchased from National Cancer Institute (Maryland, USA) or Jackson Laboratories (Maine, USA Table S1 ).
We 
IL-33/ST2 engagement in the donor T cells augments acute GvHD
Because host IL-33 is increased upon tissue injury, we examined whether Figure   5D ); interestingly, intracellular IL-4 and IL-17A levels were increased ( Figure S8C ).
These findings indicate that ST2 deficiency results in decreased IL-18R upregulation and is associated with a profound defect in production of IFN-γ, a cytokine known to contribute to GVHD severity.
17
Elevated levels of sST2 function as a decoy receptor to decrease acute GVHD Given the increased levels of sST2 prior to the development of and during GvHD in humans, we examined sST2 levels in the serum of mice after allo-HCT. Levels of sST2
For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From in the serum of mice were increased as GvHD progressed ( Figure 6A, Figure S9A ).
However, onset of the elevation of sST2 levels did not occur until after at least 2 days post transplantation ( Figure S9A ). We hypothesized that sST2 not only indicates tissue injury of GvHD but functions as a decoy receptor to regulate GvHD severity. To test this hypothesis, allo-HCT WT recipients were given exogenous soluble ST2-Fc fusion protein known to block the binding of IL-33 to the membrane bound form of ST2. 
infusions to block ST2/IL-33 interaction had significantly reduced GVHD lethality ( Figure 6B ) and lower IL-6 and IFN-γ serum levels without effects on other pro-inflammatory mediators such as IL-12, TNFα or anti-inflammatory IL-10 ( Figure   6C , Figure S9B ). Concordantly, gut and liver GVHD histopathology was significantly diminished in mice receiving ST2-Fc compared to mice receiving nonspecific IgG ( Figure   6D ). Together, these data indicate that elevated levels of soluble ST2 function to ameliorate tissue injury created by conditioning and GVHD.
Discussion
The recent identification of elevated sST2 as a biomarker of steroid-refractory GVHD and mortality 59 has raised interest in the role of IL-33 and its receptor after allo-HCT. We found reproducible results in four different labs despite differences known to affect GvHD models, such as presumed differences in microbiota between murine facilities or vendors. 65 Our results demonstrate that the IL-33/ST2 axis was proinflammatory in the immediate period after allo-HCT. IL-33/ST2 interaction on T cells elicits increased IFN-γ production, upregulation of IL-18R, and cell proliferation resulting in augmenting GVHD severity ( Figure S10A ). Blocking IL-33 interaction with ST2 by increasing levels of the sST2 receptor decreased pro-inflammatory cytokine production, tissue injury, and GVHD lethality ( Figure S10B ). In mice, sST2 acted as a negative
regulator scavenging free IL-33 and preventing it from exerting its pro-inflammatory function. This may seem contradictory to the correlation of elevated sST2 with increased GVHD severity seen in patients, however, the high levels of sST2 in patients may be the reaction of the immune system to counteract IL-33-mediated inflammation.
We favor the explanation that sST2 release into the serum comes too late in the inflammatory response leading to sST2 being overwhelmed by IL-33 resulting in its inability to quell the IL-33-mediated inflammatory effects. For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From Our finding that IL-18R was down regulated in ST2 deficient compared to WT T cells which was connected to reduced GvHD severity caused by these cells cannot be directly compared to previous studies using IL-18 deficient mice, IL-18R deficient mice or treatment with IL-18, because the experimental approaches are different. [71] [72] [73] However, consistent with our findings that the ST2 deficient T cells with lower IL-18R expression cause less GvHD the report by Min CK et al. 73 showed that IL-18R deficient donor CD8
T cells caused significantly less GVHD compared to WT T cells. Conversely, this effect was not seen when suing CD4 T cells deficient for IL-18R. Table S1 . For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From
